European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-18

Development of a novel control technology for ensuring high quality Powdered Infant Formula

Objectif

Powdered Infant Formula (PIF) is a milk-like food intended to supplement or replace the milk of the baby's mother. The quality, nutritional profile and safety of PIF are intrinsic for the health and wellbeing of the babies and infants that depend on it for their survival and growth. Since most infant formulae are required to be instant, the preferred drying approach is typically designed to allow for product agglomeration during drying. The agglomeration improves the reconstitution properties. It is important that the degree of agglomeration and its compactness can be controlled. The identified key physical parameters governing the agglomeration process include granule size/shape and the key chemical parameters include moisture content. Properties of individual agglomerates determine bulk powder properties such as powder flowability, bulk density and solubility. These are important product quality characteristics since, for example, the product is measured out on a volume basis (in scoops) whereas nutritional requirements are provided on a mass basis. Thus any changes in particle properties post drying, during conveying and packaging will have implications.
For dry blending, the ingredient distribution within granules and between granules has a critical effect on content uniformity, nutrient absorption rates and ultimately infant safety. The development of a hybrid technology that is capable of assessing the physical and nutritional characteristics of PIF in real time would significantly advance process control leading to greater product quality, process validation, and ultimately infant safety. In response the PURE-FORMULA project will develop a novel Process Analytic Technology capable of providing spatial measurements of moisture and ingredient identity from the forming PIF agglomerates. The R&D effort will centre on prototype engineering design, software/algorithm design, user interface design, integration and validation within PIF manufacturing equipment.

Appel à propositions

FP7-SME-2013
Voir d’autres projets de cet appel

Régime de financement

BSG-SME - Research for SMEs

Coordinateur

INNOPHARMA LABS LIMITED
Contribution de l’UE
€ 519 709,50
Adresse
ASHFIELD CRONE LOWER
Y14 REDCROSS
Irlande

Voir sur la carte

Région
Ireland Eastern and Midland Dublin
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Kiernan Luke (Mr.)
Liens
Coût total
Aucune donnée

Participants (9)